Awaiting development: Guidance and quality standards

Showing 51 to 60 of 291

Guidance and quality standards awaiting development
Title	Type
DB-OTO for Hearing loss [TSID12321]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID6688]	Technology appraisal guidance
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Deucravacitinib for treating active Sjogren's syndrome [TSID12342]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]	Technology appraisal guidance